CHP
KPTI icon

Cable Hill Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Cable Hill Partners’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-7
Closed -$1K – 921
2017
Q4 		$1K Sell
7
-26
-79% -$4.18K ﹤0.01% 905
2017
Q3 		$5K Buy
+33
New +$4.73K ﹤0.01% 761

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Cable Hill Partners's KPTI Position: Q1 2018 in Review

Cable Hill Partners sold out of Karyopharm Therapeutics (KPTI) in Q1 2018, closing a stake of 7 shares — an estimated $1K sold.

Cable Hill Partners first reported a position in KPTI in Q3 2017 and held it in 2 quarters. The position peaked at $5K in Q3 2017. 88 funds tracked by Wall St. Rank hold KPTI as of Q1 2018.

  • Cable Hill Partners reported no remaining Karyopharm Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Cable Hill Partners sold 7 Karyopharm Therapeutics shares in Q1 2018, an estimated $1K.
  • Cable Hill Partners first reported a position in Karyopharm Therapeutics in Q3 2017 and held it in 2 quarters.
  • Cable Hill Partners's Karyopharm Therapeutics position peaked at $5K in Q3 2017.
  • 88 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2018.

Based on Cable Hill Partners's 13F filing for Q1 2018, filed 20 Apr 2018.